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Abstract 
Sickle Cell Disease (SCD) is a hereditary monogenic disorder that affects millions 
of people worldwide and is associated with symptoms such as stroke, lethargy, chronic 
anemia, and increased mortality. SCD can be quickly detected and diagnosed using a 
simple blood test as an infant, but as of now, there is currently limited treatment to cure 
an individual of sickle cell disease. Recently, there have been several promising 
developments in CRISPR-Cas-associated gene-editing therapeutics; however, there have 
been limitations in gene-editing efficiency monitoring, which if improved, could be 
beneficial to advancing CRISPR-based therapy, especially in SCD. The CRISPR-Chip, a 
three-terminal graphene-based field effect transistor (gFET), was used to detect genomic 
samples of individuals with SCD, with and without amplificati​on. With the dRNP-HTY3’ 
complex, CRISPR-Chip was able to specifically detect its target sequence with and 
without pre-amplification. With the dRNP-MUT3’ complex, CRISPR-Chip was only able 
to specifically detect one of its two target sequences. Fa​cile detection, analysis, and 
editing of sickle cell disease using CRISPR-based editing and monitoring would be 
beneficial for simple diagnostic and gene-editing therapeutic treatment of other single 
nucleotide polymorphisms as well, such as beta-thalassemia and cystic fibrosis. 
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Introduction 
Sickle Cell Disease (SCD) is a hereditary monogenic disorder that affects millions 
of people worldwide and is associated with symptoms such as stroke, lethargy, chronic 
anemia, and increased mortality ​(Bialk et al., 2016; Park et al., 2016)​.  SCD includes all 
genotypes with at least one sickle gene and is caused by a single nucleotide 
polymorphism (SNP) in the β-globin gene (HBB) on chromosome 11, converting a GAG 
codon to a GTG codon in exon 1 ​(Bialk et al., 2016; Park et al., 2016)​. SCD can be 
quickly detected and diagnosed using a simple blood test as an infant; however, there is 
currently limited treatment to cure an individual of sickle cell disease. As of now, 
allogeneic hematopoietic stem cell transplanta​tion (HSCT) is the only treatment 
available. HSCT for SCD uses donor allogeneic stem cells from a family-related or an 
unrelated donor, from the bone marrow, peripheral blood or cord blood ​(Galgano and 
Hutt, 2018)​. These stem cells are then intravenously infused into patients with SCD. This 
treatment is an invasive procedure associated wit​h high risk of graft-versus-h​ost-disease, 
infections, and infertility, and is only feasible for approximately 15% of the patient 
population due to lack of compatible human leukocyte antigen (HLA)-matched donors 
(Kassim and Sharma, 2017; Park et al., 2016)​. 
In recent years, researchers have utilized multiple techniques to improve upon 
HSCT therapies in order to cure SCD. These techniques include viral vector-based donor 
templates and gene-editing methods such as zinc finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs), and clustered regularly-interspaced Short 
palindromic repeats (CRISPR)-associated nuclease (Cas) ​(Demirci et al., 2018; Gupta 
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and Musunuru, 2014; Lux et al., 2019; Moran et al., 2018; Sebastiano et al., 2011; Sun 
and Zhao, 2014; Tasan et al., 2016)​. 
CRISPR-Cas9-based gene-editing technology 
Compared to the other methods, CRISPR-Cas is inexpensive and demonstrates 
higher ease of use and modifiability (Gupta and Musunuru, 2014; Tasan et al., 2016). 
CRISPR-Cas9 uses a 20-nucleotide single-stranded guide RNA (sgRNA) sequence that is 
complementary that is adjacent to a protospacer adjacent motif (PAM), usually NGG 
(Anders et al., 2014; Aryal et al., 2018)​.  CRISPR-Cas9’s modifiability comes from only 
needing to change the 20-nucleotide sgRNA sequence to target any genomic sequence 
(Gupta and Musunuru, 2014)​. However, Cas9 protein size and CRISPR-Cas9’s off-target 
effects are the two main concerns regarding the CRISPR-Cas9 gene-editing method. 
Compared to the other two popular gene-editing methods, ZFN and TALENS, 
CRISPR-Cas9 is significantly larger in size, making it more difficult to deliver using viral 
vectors or as an RNA molecule ​(Gupta and Musunuru, 2014)​.  
While CRISPR-Cas9’s specificity and binding are attributed to its 20 nucleotide 
protospacer and the PAM, there have been reports of off-target cleavage activity and 
varying levels of on-target efficiency depending on the sgRNA sequence selected ​(Aryal 
et al., 2018; Fu et al., 2013; Hsu et al., 2013; Pattanayak et al., 2013)​. However, since 
these off-target effects usually stem from the sgRNA sequence, this issue can be 
mitigated by choosing a sgRNA sequence with the least known off-target effects. It is 
also important to note that many reports of high-frequency off-target activity have been 
associated with human and mouse cell-lines, but there have been few reports of off-target 
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effects in mammalian embryo editing ​(Hsu et al., 2013; Iyer et al., 2018; Nakajima et al., 
2016)​. One study done demonstrated CRISPR-Cas9’s efficiency of 80% in targeting both 
alleles of two genes in mice, which indicates CRISPR-Cas9 as a promising tool in 
gene-editing therapeutics ​(Wang et al., 2013)​.  
Multiple studies have used CRISPR/Cas9 genome editing technology to correct 
the sickle cell mutation in CD34+ hematopoietic stem and progenitor cells (HSPCs) and 
have demonstrated relatively high editing efficiencies and clinically relevant gene-editing 
rates (DeWitt et al., 2016; Hoban et al., 2016; Lin et al., 2017; Park et al., 2016; Tasan et 
al., 2016). These results are indicative of the possible applications of CRISPR/Cas9 in 
targeting the specific mutation in SCD. Using CD34+ HSPCs​ ​from patient with SCD, one 
lab used CRISPR-Cas9 with a single-stranded DNA oligonucleotide donor (ssODN) to 
achieve efficient correction of the SCD mutation in human HSPCs ​(DeWitt et al., 2016)​. 
The edited HSPCs produced less sickle hemoglobin RNA and protein, as well as 
demonstrated increased levels of wild-type hemoglobin upon differentiating into 
erythroblasts. Immunocompromised mice were treated ​ex vivo ​with engraftment of the 
human HSPCs, and the HSPCs maintained the SCD gene edits for sixteen weeks at levels 
indicative of having clinical benefit.  
Another study used both TALENs and CRISPR-Cas9 methods to target the sickle 
cell mutation in HBB to evaluate on-target and off-target cleavage rates ​(Hoban et al., 
2016)​. To measure these gene modification rates through homology directed repair 
(HDR), they co-delivered TALENs and CRISPR-Cas9 to K562 3.21 cells, which contain 
the sickle mutation, with a homologous donor template containing the HBB gene. While 
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TALENs demonstrated average gene modification rates between 8.2% - 26.6%, 
CRISPR-Cas9 produced an overall higher rate of 4.2 - 64.3% and thus was chosen to 
facilitate SCD correction in HSPCs. CRISPR-Cas9 delivery to HSPCs demonstrated ​in 
vitro​ gene modification rates in HSPCs at over 18%. To test CRISPR-Cas9’s clinical 
applications, the lab corrected the SCD mutation in bone-marrow derived CD34+ HSPCs 
from patients with SCD, which resulted in wild-type hemoglobin production, further 
supporting CRISPR-Cas9’s use as gene-editing tool for patient with SCD. Current 
methods of ​ex vivo ​CRISPR/Cas9-based gene-editing techniques have only been tested ​in 
vitro​ human cell cultures or ​in vivo​ mouse models, and there are currently no research 
trials involving humans directly ​(DeWitt et al., 2016; Hoban et al., 2016)​. However, 
clinical trials are on the horizon, meaning CRISPR-Cas9 ​ex vivo​ editing of 
SCD-associated mutations will need to be constantly monitored before any potential 
reintroduction into patients. 
Besides genome editing, gene therapy monitoring and diagnostics are emerging 
applications in the CRISPR-Cas systems (Mintz et al., 2018; Uppada et al., 2018). In a 
recent study, researchers developed a new technology with sensitivity and specificity in 
detecting unamplified target DNA sequences with the insertion of the ​bfp​ (blue 
fluorescent protein) gene and large fragment deletions relevant in Duchenne muscular 
dystrophy clinical samples ​(Hajian et al., 2019)​. This new technology termed 
CRISPR-Chip, a graphene-based field effect transistor with CRISPR/dCas9 immobilized 
on the surface, has potential to play a part in the development of CRISPR-based therapy 
as a gene-editing monitoring tool. 
8 
 
Conventional nucleic acid-based detection methods require amplification of the 
target genome sequences, such as PCR, in order to validate the presence of a target gene 
(Cao et al., 2017; Hudecova, 2015)​. In addition, many nucleic acid detection technologies 
are expensive, require multi-step processes as well as bulky, complex instruments, which 
are time-consuming and require trained personnel for operation. CRISPR-Chip 
overcomes these limitations as it is a hand-held, label-free device that is affordable, easy 
to use, and only requires a short amount of time for target gene detection. 
 
CRISPR-Chip background information 
CRISPR-Chip is comprised of two main parts: its graphene-based field effect 
transistor (gFET) platform and an immobilized CRISPR-nuclease dead cas9 (dcas9) 
protein complex. This graphene substrate was chosen as it is known for its excellent 
electrical conductivity, large surface area, and high sensitivity to the adsorption and 
interactions of charged molecules ​(Peña-Bahamonde et al., 2018; Pumera, 2011)​. ​The 
CRISPR-Chip is a CRISPR-enhanced, three-terminal gFET, with source, drain, and 
liquid-gate electrodes as shown in Figure 1 (Hajian et al., 2019).  
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Figure 1. CRISPR-Chip graphic: the CRISPR-Chip, a graphene field effect transistor,           
with immobilized dCas9 and sgRNA is able to detect its target sequence. Reproduced             
from “Detection of unamplified target genes via CRISPR–Cas9 immobilized on a           
graphene field-effect transistor,” by R. Hajian et al., 2019, ​Nature Biomedical           
Engineering​. Copyright 2019 by Springer Nature. Reprinted with permission.  
 
The immobilized dead cas9 protein complex contains a 20-nucleotide 
single-stranded guide-RNA (sgRNA) molecule bound as a ligand. This complex is 
termed as dRNPs (dead cas9- ribonucleoproteins) hereafter. The sgRNA can be easily 
designed to complement a specific target sequence. The designs of the sgRNAs used in 
this study will be discussed in the Materials and Methods section (pg. 14). The dRNP, 
similar to CRISPR-Cas9 activity, will probe the entire genomic sample until it finds its 
target sequence; however, since the NUC lobe of the dcas9 is catalytically inactive, 
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instead of cleaving its target sequence, the dRNP will unzip the double helix and the 
sgRNA will bind upstream of the protospacer adjacent motif (PAM) ​(Boyle et al., 2017; 
Jiang and Doudna, 2017)​.  
The biosensor is functionalized with dRNP immobilization onto the graphene chip 
via a molecular linker, ​1-pyrenebutanoic acid (PBA). First, PBA non-covalently binds 
with the graphene surface through π–π aromatic stacking interactions, followed by 
covalent binding of PBA’s carboxylate group to the dCas9 protein, tethering the protein 
onto the CRISPR-Chip. As shown in Fig 2, any PBA molecules that do not have any 
attached dCas9 will be blocked by amino-polyethylene glycol 5-alcohol (PEG); however, 
what is not shown in the figure, subsequent addition of ethanolamine hydrochloride. 
These blocking molecules (known in the protocol as Quench 1 and Quench 2) are 
important as they hinder any non-specific adsorption or binding of charged molecules 
onto the graphene surface. After immobilizing dCas9 onto and saturating the graphene 
platform, sgRNA is added onto the chip to conjugate with the dCas9 to create the dRNP 
complex. More information on the protocol can be found in the Materials and Methods 
sectio​n (pg. 17-19).  
 
11 
 
 
Figure 2. Schematic of CRISPR-Chip functionalization. Adapted from “Detection of          
unamplified target genes via CRISPR–Cas9 immobilized on a graphene field-effect          
transistor,” by R. Hajian et al., 2019, ​Nature Biomedical Engineering​. Copyright 2019 by             
Springer Nature. Reprinted with permission.  
 
The CRISPR-Chip is inserted to a hand-held reader that is connected to a 
computer program which displays the response. The functionalization of the graphene 
surface acts as a channel between the source and drain electrodes, with the third terminal 
being a liquid gate that interacts with the genomic sample which is contained in a 
reaction buffer. Voltage is applied across the surface between the liquid-gate and source 
electrodes (Vg). Due to graphene’s sensitivity to interactions with charged molecules on 
its surface, binding of the negatively-charged target DNA to the RNP will modify the 
conductivity of graphene, and this binding will be read by the CRISPR-Chip reader as an 
electrical current. Binding of the target DNA with the dRNP will result in a larger 
electrical output signal from the reader while minimal binding of non-target DNA with 
the dRNP will result in a significantly smaller electrical response. For more detailed 
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description of the CRISPR-Chip operational and measurement methods, please refer to 
the Hajian 2019 paper.  
Earlier this year, the CRISPR-Chip successfully analyzed DNA samples collected 
from HEK293T cell lines that expressed ​bfp​ and clinical samples of DNA of patients with 
Duchenne muscular dystrophy (DMD) ​(Hajian et al., 2019)​. They were able to detect and 
differentiate genomic samples of DNA with and without ​bfp​ or DMD. The lab tested two 
different clinical samples of DMD: one containing deletion of exon 3 and the other 
containing deletion of exon 51. They used clinical samples of healthy patients as a 
control. The CRISPR-Chip detection of DMD is a break-through technology as it can be 
used as an inexpensive and facile diagnostic tool in a clinical setting. In addition, the 
ability of the CRISPR-Chip to detect target sequences in a genomic sample without 
amplification of the target sequence demonstrates its sensitivity and specificity.  
 
Single nucleotide polymorphisms  
A single nucleotide polymorphism (SNP) is a single nucleotide base mutation, in 
which one of the bases (A, T, C, G) are replaced with another base. Sickle cell disease is 
caused by a SNP, and while it is one of the diseases that can be easily diagnosed by a 
simple blood test, detecting SNPs in general has proven difficult. Current methods of 
detecting SNPs require complex processes and  amplification of the target sequence in 
order to achieve detection and have poor specificity and sensitivity ​(Ficht et al., 2004; 
Gerion et al., 2003; Xiao et al., 2009​). Recently,  there has been more development in 
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using electrical biosensors, which have lowered the limit of detection of target DNA to 
the femtomolar level ​(Lu et al., 2014; Ping et al., 2016)​.  
 
Objective 
In this study, I hypothesize that we will be be able to use the CRISPR-Chip 
platform to detect the sickle cell disease-associated SNP without amplification. 
Compared to the indels from the ​bfp​ gene and from the mutations in DMD, the sickle cell 
associated-SNP may be more difficult to detect from unamplified genomic samples as the 
SCD target sequence only has one base pair difference to a healthy genomic sequence, as 
well as due to the promiscuity of the CRISPR-Cas system ​(Tsai et al., 2017)​. If a sgRNA 
has high off-target activity, this may inhibit our ability to detect a single mismatch in the 
dRNP target sequence. As the CRISPR-Cas9 gene-editing technology is already known 
for its off-target effects, this may be a challenge for using the CRISPR-Chip to detect a 
SNP. However, successes of SCD correction in HSPCs using CRISPR-Cas9 shown in 
previous literature, as well as the sensitivity and specificity of the CRISPR-Chip, are 
promising in optimizing the CRISPR-chip device in detecting the SCD-associated SNP 
(DeWitt et al., 2016; Hajian et al., 2019; Hoban et al., 2016)​. 
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Materials and Methods 
Single guide RNA (sgRNA) design 
For sickle cell disease (SCD) analysis via CRISPR-Chip, 3 sgRNAs were 
designed utilizing multiple sgRNA designing programs and a sgRNA used in previous 
literature ​(Bialk et al., 2016)​. The HBB gene was input into these programs, and the 
sgRNA sequences chosen targeted sequences in exon 1 where the single point mutation 
causing SCD was located. The first sgRNA sequence, termed sgRNA MUT 3’, targeted a 
sequence with the SCD mutation: 5’ GTAACGGCAGACTTCTC​CAC 3’​. The sgRNA 
was named sgRNA MUT3’ because the SCD mutation is the second base pair from the 3’ 
end. sgRNA MUT3’ was designed based off of online sgRNA design programs: GUIDES 
Designer, Chop Chop, CRISPOR, and Synthego. The second sgRNA sequence, termed 
sgRNA MUT 5’, targeted a different sequence with the same SCD mutation: 5' 
CTCAGGAGTCAGATGCACCA 3'. sgRNA MUT5’ was termed this name because the 
SCD mutation is the second base pair from the 5’ end. sgRNA MUT5’ was designed 
based off of online sgRNA design programs: DNA 2.0, CRISPOR, and Synthego. The 
third sgRNA sequence, termed sgRNA HTY 3’, targeted the same sequence as sgRNA 
MUT3’ without the SCD mutation: 5’ GTAACGGCAGACTTCTC​CTC 3’​. sgRNA 
HTY3’ was generated by online sgRNA design programs: GUIDES Designer, Chop 
Chop, CRISPOR, and Synthego. In addition, sgRNA HTY3’ has also been successfully 
used to cleave the target sequence in previous literature ​(Bialk et al., 2016)​. 
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sgRNA selection and design schematic  
Target sequence:         5’ GTAACGGCAGACTTCTCC​T​C 3’ 
 
Sickle cell mutation:    5’ GTAACGGCAGACTTCTCC​A​C 3’  
 
sgRNA sequence:         5’ ​GUAACGGCAGACUUCUCC​A​C 3’ 
 
sgRNA sequences (5’ to 3’) 
sgRNA MUT 3’: ​GUAACGGCAGACUUCUCC​A​C 
sgRNA HTY 3’:  GUAACGGCAGACUUCUCC​U​C 
sgRNA MUT 5’: C​A​CAGGAGUCAGAUGCACCA 
 
Primer selection 
For validation of the designed sgRNAs, primers were designed using Thermo 
Fisher Scientific’s Primer Design Tool. The HBB gene was inputted into the program, 
and 3 paired primers that encompassed the entirety of exon 1 were produced. All 3 paired 
primers were guaranteed to have a 95% success rate in sequencing viability, and the 
longest amplicon length (506 base pairs) was chosen as caution to capture the entire exon 
1 and for better visibility during PCR. The forward and reverse primer sequences were 
TTGAGGTTGTCCAGGTGAGCCA and GGCCAATCTACTCCCAGGAGCA 
respectively. 
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Genomic DNA sample selection 
Human genomic ​samples from two male patients affected by sickle cell disease 
were purchased with certificate of analysis from Coriell Institute for Medical Research 
(Camden, NJ). Sample SCD1 (NA16265) is a sample from a 19-year old African 
American male with homozygous sickle cell diseases (HbSS). Sample SCD2 (NA16267) 
is a sample from a 3-year old African American male with two copies of the sickle cell 
mutation. The concentrations were routinely measured prior to incubation with 
CRISPR-Chip using Infinite M200 Nanoquant (Tecan). 
 
PCR protocol 
HBB ​exon 1​ ​was ampli​fied from 100ng​ genomic ​DNA via PCR according to 
manufacturer's protocols. ​In a 50​µL reaction mixture, the following reagents were used: 
100ng genomic DNA (​NA16265, NA16267​), 10 µL 5X Phusion HF Buffer, 1 µL dNTP, 
5 µL forward primer, 5 µL reverse primer, 0.5 µL Phusion DNA polymerase and, ​X ​µL 
H2O (X denotes the remaining solution needed to create a ​50​µL mixture). ​The following 
PCR thermal cycler protocol was used (PTC-100: Programmable Thermal Controller, MJ 
Research Inc., U.S.): (1) 98˚C for 30 sec (2) 98˚C for 10 sec (3) 63.5˚C for 30 sec (4) 
72˚C for 15 sec (5) repeat 2-4 29x (6) holding at 72˚C for 5 min prior to cooling to 4˚C. 
The forward and reverse primer sequences were TTGAGGTTGTCCAGGTGAGCCA 
and GGCCAATCTACTCCCAGGAGCA respectively. 2 µL of the PCR products were 
loaded on a 1% agarose gel 100V for 1hr, followed by an ethidium bromide bath  
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(0.5µg/ml, 30min). Once stained, the gel was imaged using the UVP ChemStudio 
(Analytikjena, Germany) 
 
CRISPR-Chip Molecular Linker Functionalization and Activation 
Naked graphene FET chips were obtained (Cardea, San Diego CA) and cleaned 
w​ith 30µL acetone twice and 30µL deionized water (DIW) once. The chips were 
subsequently functionalized with 1-pyrenebutanoic acid (PBA) (5mM, 15 µl) in 
dimethylformamide (DMF) for 2 hours at room temperature or overnight at 4˚C. 
Following the incubation, the graphene sensor was rinsed with 30µL DMF twice and 
30µL DIW once. The PBA was activated using a 1:1 volume ratio of 
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC, 4mM) and 
N-hydroxysuccinimide (NHS, 11mM) (Sigm​a Aldrich) in 50 mM of 2-(N-Morpholino) 
ethanesulfonic acid (MES, pH 6) for 5 minutes at room temperature according to 
published literatures prior to incubation with dCa​s9 ​(Everaerts et al., 2008; Wang et al., 
2011​). 
 
CRISPR–Chip evaluation for the detection of SCD in the presence of Amplicons  
The dRNP-HTY3’ and dRNP-MUT3’ functionalized CRISPR-Chips were 
calibrated with 2mM MgCl2 for 5min at 37 °C and subsequently incubated with 900ng of 
amplicons SCD1 or SCD2 (30 µl in 2mM MgCl2) for 25min at 37 °C. For the control 
experiments, amplicons of healthy DNA without the SCD mutation or amplicons without 
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the HBB sequence were incubated with dRNP-HTY3’- and dRNP-MUT3’-functionalized 
CRISPR–Chips. For all experiments, the sensor was rinsed (2mM MgCl2, 30 µl) for 
15min at 37 °C after incubation with the genomic sample. 
 
CRISPR–Chip detection of SCD in the presence of Genomic DNA 
The dRNP-HTY3’-functionalized CRISPR–Chips were calibrated with 2mM 
MgCl2 for 5min at 37 °C and subsequently incubated with 1800ng SCD1 or SCD2 DNA 
(30µl in 2mM MgCl2). For the control experiments, 1800ng of healthy human embryonic 
kidney (HEK) DNA was incubated with dRNP-HTY3’-functionalized CRISPR-Chips. 
For all experiments, the CRISPR–Chip response was continuously monitored for 
25 minutes at 37 °C. CRISPR–Chips were then rinsed (2mM MgCl2, 30 µl) for 15 
minutes at 37 °C after incubation with the genomic sample. 1800ng genomic DNA was 
used instead of 900ng because initial tests of 900ng genomic DNA samples were too low.  
 
CRISPR-Chip Complete Assay Protocol 
1. Calibration of PBA-functionalized chips with 50mM MES for 5 minutes. 
2. Activate the PBA linker with a mixture of 4mM EDC and 11mM NHS for 5 
minutes. 
3. Rinse any unbound PBA linker with 50mM MES (2x) for 1 minute. 
4. Association of the PBA linker with 900ng (30 µl in 2 mM MgCl2) dCas9 for 15 
minutes.  
5. Association of Quench 1 containing 1mM amino-PEG5-alcohol for 10 minutes.  
19 
 
6. Association of Quench 2 containing 1M ethanolamine hydrochloride for 10 
minutes.  
7. Rinse any unbound Quench 1 and Quench 2 with 2mM MgCl​2 ​(5x) for 1 minute. 
8. Calibration for sgRNA with 2mM MgCl​2 ​for 5 minutes. 
9. Association of 900ng (30 µl in 2 mM MgCl2) sgRNA for 10 minutes. 
10. Rinse away any unbound sgRNA and calibrate for DNA with 2mM MgCl​2 ​for 5 
minutes. 
11. Association of Xng (30 µl in 2 mM MgCl2) DNA for 25 minutes. (X= 900ng or 
1800ng, depending on the type of sample used).  
12. Rinse of any unbound DNA with 2mM MgCl​2​ for 15 minutes. 
 
CRISPR-Chip Sensor Response, Measurement, and Analysis Methods 
The sensor response was recorded in real-time as shown in Figure 3, and the data 
were analyzed using equation below, which was used in previous literature ​(Hajian et al., 
2019)​. Each chip consists of three transistors that separately measure the current, and 
these individual transistor responses can be analyzed separately.  I​ds​ is the signal after 
incubation with the DNA sample and subsequent rinsing. I​ds0​ is the calibration baseline 
signal after the assay buffer was incubated during calibration. The calibration step takes 
into account sensor-to-sensor variation and effects of the buffer. I-response (%) the unit 
of measure, is the percentage change in between I​ds0 ​(calibration baseline) and I​ds​ (the 
response after rinsing of the target DNA).  
I-response (%) = Ids0
100(Ids−Ids0)  
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Figure 3. ​Real-time ​CRISPR-Chip I-Response (%), average current, is monitored          
throughout sensor functionalization and analysis with dRNP-HTY3’. The yellow line          
indicates the I-Response (%) of dRNP-HTY3’-Healthy Genomic DNA and the blue line            
indicates the I-Response (%) of dRNP-HTY3’-SCD1 Genomic DNA​. The white regions           
represent rinsing and calibration with 2mM ​MgCl2​. 
 
 
Results 
Selectivity of the immobilized dRNP-HTY3’ with amplicon sequences 
CRISPR-Chip’s detection of the SCD mutation was first tested using amplicon 
sequences of two different DNA samples containing the SCD mutation. The first control 
was amplicon sequences from healthy DNA without the SCD mutation, and the second 
control (Scram) was amplicon sequences that did not include the HBB gene sequence. 
The PCR protocol for DNA amplification can be found in the Methods section. Each 
combination of dRNP-HTY3’ with (900ng Amplicon) was ran at least three times.  
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I found evidence to support selective binding and detection of dRNP-HTY3’ for 
Healthy amplicon. The average responses of the four amplicon samples (Healthy, SCD1, 
SCD2, and Scram) were different, with Healthy amplicon with the highest average 
response at 10.04 and Scram amplicon with the lowest response at 5.67 (One-Way 
ANOVA: F​3, 39 ​= 8.044, p = 0.000272, Fig. 4). A post-Tukey test was performed and 
further supports dRNP-HTY3’ complex’s higher affinity of binding with Healthy 
amplicon. The results are shown in the Table 1 (* notes statistical significance). 
 
Figure 4. ​The relationship between dRNP-HTY3’ (900ng amplicon type) and average 
I-Response (%). Bar heights and bars represent means ± standard deviation. ​Healthy 
(n=10), SCD1 (n=15), SCD2 (n=9), Scram (n=9) (n= number of working transistors). 
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Table 1.​ Post-Tukey analysis of dRNP-HTY3’ sensor responses of amplicon samples  
Amplicon Comparison P-adjusted value 
Healthy-SCD1 * 0.0042601 
Healthy-SCD2 * 0.0251331 
Healthy-Scram * 0.0001736 
SCD1-SCD2 0.9917302 
SCD1-Scram 0.3807639 
SCD2-Scram 0.3361175 
 
 
Specificity of the immobilized dRNP-HTY3’ with genomic sequences 
Genomic DNA samples of Healthy DNA extracted from HEK cells and the two 
different DNA samples containing the SCD mutation were tested with the dRNP-HTY3’ 
complex.​ ​ Each combination of dRNP-HTY3’ with (1800ng Genomic Sample) was ran at 
least two times.  
I found evidence to support selective binding and detection of dRNP-HTY3’ for 
Healthy amplicon. The average responses of the three genomic samples (Healthy, SCD1, 
and SCD2) were different, with Healthy genomic sample with the highest average 
response at 4.48 and SCD1 genomic sample with the lowest response at 0.57 (One-Way 
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ANOVA: F​2, 24 ​= 58.87, p = 5.55e-10, Fig. 5). A post-Tukey test was performed and 
further supports dRNP-HTY3’ complex’s higher affinity of binding with Healthy 
genomic sample. The results are shown in the Table 2 (* notes statistical significance). 
 
 
Figure 5. ​The relationship between dRNP-HTY3’ (1800ng genomic type) and average 
I-Response (%). Bar heights and bars represent means ± standard deviation. Healthy 
(n=6), SCD1 (n=12), SCD2 (n=9) ​(n= number of working transistors). 
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Table 2.​ Post-Tukey analysis of dRNP-HTY3’ sensor responses of genomic samples  
Amplicon Comparison P-adjusted value 
Healthy-SCD1 * 0.0000000 
Healthy-SCD2 * 0.0000003 
SCD1-SCD2 * 0.0082045 
 
 
Specificity of the immobilized dRNP-MUT3’ with amplicon sequences 
We tested for selectivity of the SCD SNP using the dRNP-MUT3’ complex with 
the four amplicons tested previously with dRNP-HTY3’. Each combination of 
dRNP-HTY3’ with (900ng Amplicon) was ran at least two times.  
I found evidence to support selective binding and detection of dRNP-MUT3’ for 
SCD1 amplicon; however, there was no evidence to support selective binding and 
detection of dRNP-MUT3’ for SCD1 amplicon. The average responses of the four 
amplicon samples (Healthy, SCD1, SCD2, and Scram) were different, with SCD1 
amplicon sample with the highest average response at 10.94 and Scram amplicon sample 
with the lowest response at 4.75 (One-Way ANOVA: F​3, 35 ​= 11.38, p = 2.33e-05, Fig. 6). 
A post-Tukey test was performed and further supports dRNP-HTY3’ complex’s higher 
affinity of binding with SCD1 sample. While the average I-Responses of SCD1 and 
SCD2 are similar, there is no statistical significance between average I-Responses 
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between SCD2 amplicon and Healthy amplicon (Post-Tukey: p-adj = 0.7444647). The 
results are shown in the Table 3 (* notes statistical significance). 
 
 
Figure 6. ​The relationship between dRNP-MUT3’ (900ng amplicon type) and average 
I-Response (%). Bar heights and bars represent means ± standard deviation.​ Healthy 
(n=9), SCD1 (n=12), SCD2 (n=6), Scram (n=12) (n= number of working transistors). 
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Table 3.​ Post-Tukey analysis of dRNP-MUT3’ sensor responses of amplicon samples  
Amplicon Comparison P-adjusted value 
Healthy-SCD1 * 0.0018922 
Healthy-SCD2  0.1336568 
Healthy-Scram  0.7444647 
SCD1-SCD2 0.6687290 
SCD1-Scram * 0.0000300 
SCD2-Scram * 0.0130985 
 
 
Conclusion and Future Directions 
The use of gFET biosensors has become increasingly popular for detecting large 
molecules in biomedical, clinical, and environmental applications ​(Afsahi et al., 2018; 
Forsyth et al., 2017; Justino et al., 2017)​. The CRISPR-Chip, a gFET biosensor with 
immobilized catalytically inactivated CRISPR-Cas9 complex, was able to specifically 
detect target DNA sequences with and without the sickle cell disease-associated single 
nucleotide polymorphism in both amplicon and genomic samples. The CRISPR-Cas9 
complex capturing mechanism is easily modifiable through sgRNA selection since the 
sgRNA chosen is target-specific.  
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As shown in the Results section, with the dRNP-HTY3’ complex, the 
CRISPR-Chip was able to specifically detect the target sequences of healthy patient, with 
and without pre-amplification. With the dRNP-MUT3’ complex, the CRISPR-Chip was 
able to specifically detect one of the amplified target sequences from a patient with sickle 
cell disease. The differences in average current response between the SCD1 and SCD2 
samples could be due to patient-to-patient variation. For further testing of this possible 
patient variation, future directions would consist of including a third DNA sample of 
another patient with sickle cell disease, as well as conducting additional trials to detect a 
possible pattern of difference between the patient samples. It is also important to note that 
sgRNA-MUT3’ is based off of sgRNA-HTY3’, which has been previously used in 
literature. sgRNA-MUT3’ and sgRNA-MUT5’, which were modified to contain the 
SCD-associated SNP, may have unexpected off-target effects that could affect its binding 
with the target and non-target DNA sequences. The large range in standard deviation of 
average current could be attributed to chip-to-chip variability, as well as variation in 
enzyme activity due to the length of the assay. 
Nonetheless, the collected data shows promising indications for CRISPR-Chip’s 
ability to specifically detect and differentiate between DNA samples from a healthy 
individual and DNA samples from individuals who have sickle cell disease as there are 
obvious and statistically supported differences in average current responses. Future 
directions include conducting more data with additional trials as mentioned before, and to 
run experiments of the dRNP-MUT3’ complex with genomic samples and of the 
dRNP-MUT5’ complex with both amplicon and genomic samples.  
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Researched have already demonstrated CRISPR-Chip’s promising diagnostic 
potential for genetic diseases with samples containing insertions (BFP) as well as with 
samples containing clinically relevant deletions (DMD) ​(Hajian et al., 2019)​.  As sickle 
cell disease can already be diagnosed with a simple blood test at birth, CRISPR-Chip’s 
capacity for SCD-associated SNP detection has potential as a gene-editing monitoring 
tool for both efficiency and efficacy. Facile detection, analysis, and editing of sickle cell 
disease using CRISPR-based editing and monitoring would be beneficial for simple 
diagnostic and gene-editing therapeutic treatment of other single nucleotide 
polymorphisms as well, such as beta-thalassemia and cystic fibrosis. 
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